ANP Insider Trading

Insider Ownership Percentage: 16.34%
Insider Buying (Last 12 Months): A$34,500.00
Insider Selling (Last 12 Months): A$0.00

Antisense Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Antisense Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Antisense Therapeutics Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for ANP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Antisense Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/29/2023James GarnerInsiderIssued6,690,000A$0.06A$401,400.00
11/17/2023James GarnerInsiderBuy100,000A$0.06A$6,100.00
9/26/2023Ben PriceInsiderBuy400,000A$0.07A$28,400.00
8/22/2023Charmaine GittlesonInsiderIssued600,000A$0.05A$30,000.00
5/8/2023James GarnerInsiderBuy300,000A$0.07A$22,200.00
10/3/2022Ben PriceInsiderBuy701A$0.08A$58.18
9/29/2022Ben PriceInsiderBuy493,896A$0.09A$41,981.16
4/28/2022Mark DiamondInsiderBuy244,687A$0.11A$26,915.57
12/22/2021Mark DiamondInsiderIssued470,549A$0.24A$112,931.76
11/8/2021Charmaine GittlesonInsiderBuy133,333A$0.23A$30,666.59
See Full Table

SEC Filings (Institutional Ownership Changes) for Antisense Therapeutics (ASX:ANP)

12.29% of Antisense Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Antisense Therapeutics logo
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.
Read More on Antisense Therapeutics

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A


1,318,309 shs

Average Volume


Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Antisense Therapeutics?

Antisense Therapeutics' top insider shareholders include:
  1. Ben Price (Insider)
  2. Charmaine Gittleson (Insider)
  3. James Garner (Insider)
Learn More about top insider investors at Antisense Therapeutics.